A 5‐Azetidinyl BODIPY–Olaparib Conjugate for PARP‐Targeted Nuclear and Orthotopic Oral Tumor Imaging
ChemMedChem · 2026
DOI: 10.1002/cmdc.70450 ↗At a glance
Journal article in ChemMedChem, 2026. Written by Kaixiang Yan and 3 co-authors. Institution: School of Pharmaceutical Sciences, Fudan University, Shanghai, P. R. China. Major MEDLINE topics: Boron Compounds, Fluorescent Dyes, Piperazines, Mouth Neoplasms. 44 references. The full text is freely available in PubMed Central. Funded by: National Natural Science Foundation of China.
Abstract (original language)
Poly(ADP‐ribose) polymerase (PARP) is a clinically validated therapeutic target and an attractive biomarker for fluorescence‐guided tumor imaging. However, the nuclear localization of PARP imposes a stringent requirement on probe design, as fluorophore installation must not compromise nuclear entry of the targeting ligand. Herein, we report a focused series of 5‐azetidinyl BODIPY–olaparib conjugates as PARP‐targeted fluorescent probes. By attaching olaparib‐derived ligands to the 5‐position of the BODIPY core through flexible linkers, we sought to preserve conformational flexibility while introducing a donor–acceptor fluorophore with an enlarged Stokes shift. Among the synthesized probes, 1a exhibited the most favorable cellular imaging performance, showing efficient nuclear localization in PARP‐overexpressing U87 and Cal27 cells. Competitive blocking with olaparib and comparison with HEK293 cells supported PARP‐dependent imaging. In Cal27 xenograft and orthotopic oral tumor models, 1a showed rapid tumor accumulation and clear tumor visualization. It provides a wider range of probe options for intraoperative tracking of oral tumors.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Pharmaceutical Sciences, Fudan University, Shanghai, P. R. China.
ORCID profiles: Xiaochun Dong, Weili Zhao
Funding
- National Natural Science Foundation of China
Cite
APA
Yan, K., Qi, H., Dong, X., & Zhao, W. (2026). A 5‐Azetidinyl BODIPY–Olaparib Conjugate for PARP‐Targeted Nuclear and Orthotopic Oral Tumor Imaging. ChemMedChem. https://doi.org/10.1002/cmdc.70450
Vancouver
Yan K, Qi H, Dong X, Zhao W. A 5‐Azetidinyl BODIPY–Olaparib Conjugate for PARP‐Targeted Nuclear and Orthotopic Oral Tumor Imaging. ChemMedChem. 2026. doi:10.1002/cmdc.70450
BibTeX
@article{Yan2026,
author = {Yan, Kaixiang and Qi, Hengkai and Dong, Xiaochun and Zhao, Weili},
title = {A 5‐Azetidinyl BODIPY–Olaparib Conjugate for PARP‐Targeted Nuclear and Orthotopic Oral Tumor Imaging},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.70450}
}
EUVIMED